[p73 polymorphisms and clinicopathologic characteristics in breast cancer].
To evaluate the correlations between p73 G4C14-A4T14 polymorphisms and clinicopathologic characteristics of patients with breast cancer. A total of 170 patients with breast cancer were genotyped for p73 G4C14-A4T14 polymorphisms by Sequenom MassArray® iPLEX GOLD System. The correlations between polymorphisms and the age of patients with breast cancer, or tumor size were analyzed by t-test;the correlations between polymorphisms and clinicopathologic characteristics in patients with breast cancer were analyzed by Χ(2) test; and the relation between polymorphisms and the efficacy of chemotherapy for breast cancer was assessed by logistic regression. There was negative correlation between p73 polymorphisms and ser veral clinicopathological characteristics, including age, tumor size, menopausal status, TNM classification, pathological type, axillary lymph node metastasis, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and p53(P>0.05). The frequency of GC/GC genotype in patients with "triple negative" breast cancer (estrogen receptor -negative, progesterone receptornegative, and human epidermal growth factor receptor 2-negative) was higher than that of patients with non-triple negative breast cancer (78.9% vs 57.6%, Χ(2)=5.741, P=0.017). P73 polymorphism was negatively correlated with chemosensitivity for anthracycline-based chemotherapy (P>0.05). P73 G4C14-A4T14 polymorphisms are positively correlated with triple negative breast cancer, and the patients with breast cancer who carry GC/GC genotype may have bad prognosis.